PRP results vary because “PRP” is not one product. What reaches the joint or tendon depends on the platelet dose actually delivered and on how the concentrate was prepared, and both differ widely between protocols. A 2025 narrative review in the Journal of Clinical Medicine, covering platelet-rich plasma in sports medicine indications including osteoarthritis, tendinopathy, and muscle injury, reports that optimal therapeutic outcomes are achieved when platelet doses exceed 3.5 billion per injection, with cumulative doses of 10 to 12 billion across multiple treatments.
What “PRP dose” means when two preparations are compared
Patients usually assume PRP is a single product with a single dosing standard. In practice, dose is decided by the processing method and by what is measured in the final concentrate — not by the label on the treatment.
That is why two injections both described as PRP can deliver very different numbers of platelets to the same target.
Dose can be defined three different ways
Across protocols, a dose target may be expressed as platelets per microliter, platelets per injection, or cumulative platelets across a course of treatment. A preparation that satisfies one of those definitions will not necessarily satisfy another.
The review above notes that many studies report only platelet concentration or enrichment factors rather than absolute platelet numbers, which is exactly why the three definitions get conflated. The practical question to ask any clinic is what the final platelet dose is, how it is defined, and whether it is measured or assumed.
Preparation quality changes composition, not just platelet count
Leukocyte-rich versus leukocyte-poor
Leukocyte content is not a cosmetic detail. It shapes the inflammatory signaling environment in the treated tissue, and protocols choose a leukocyte profile deliberately based on the target.
For intra-articular use, the same 2025 review reports that leukocyte-poor PRP, characterized by reduced neutrophil content, demonstrates superior efficacy compared with leukocyte-rich PRP. The authors also note that in tendon and muscle applications the question remains debated, so the intra-articular finding should not be generalized to every site.
Red blood cell contamination and pre-activation
The same review identifies red blood cell contamination and pre-activation as detrimental to PRP effectiveness, and argues on that basis for standardized preparation protocols. If a concentrate is activated before it is placed, or carries a significant red cell load, it does not behave the way the protocol assumed.
Processing method matters measurably here. In a randomized study of 150 patients with knee osteoarthritis published in Scientific Reports in 2021, adding a 1 micron filtration step to manual PRP processing improved platelet recovery to as much as 90%. The same blood, prepared differently, yields a different injection.
Why the published research looks inconsistent
Patients reading the literature find contradictory results and reasonably conclude that PRP is unpredictable. A large part of that inconsistency is a reporting problem rather than a biological one.
The 2025 review documents that across the PRP trials it examined, only a small minority provided a comprehensive protocol description, and only about a quarter reported PRP composition quantitatively. When the intervention is not described, two trials labelled the same way may have delivered materially different products.
Methodological quality compounds it
The same review reports an analysis of PRP-related publications in which a substantial proportion contained methodological errors and a meaningful share were judged unreliable. Inconsistent measurement and reporting make outcomes look less predictable than the underlying biology may actually be.
Clinically, we treat a PRP course as a process with checkpoints rather than a single event with a verdict.
Terrain factors that change your response
PRP is not injected into a vacuum. Even with dose and preparation controlled, the tissue it lands in is shaped by your systemic metabolic state.
When joint pain tracks with metabolic stress rather than with activity, addressing the local target alone tends to produce short-lived results. That framing is set out in our writing on the biological terrain, and it is why the metabolic work is sequenced alongside any injection rather than after it.
Structural stage sets the ceiling
Where imaging shows advanced disease, the realistic goal changes. In advanced knee osteoarthritis we frame PRP framed as the practice positions it — a safe bridge therapy prior to arthroplasty — and we do not claim it regrows cartilage. Conservative measures come first, and where they have genuinely been exhausted, surgery is available here; Dr. Gurpreet Singh Padda, MD, MBA, MHP is a surgeon.
Delivery target is part of the answer
Where the concentrate is placed determines what it can act on. Intraosseous PRP aims at bone marrow-adjacent signaling, and subchondral PRP places the injection near the subchondral bone that supports joint loading — both are chosen against a specific clinical hypothesis about the pain generator, not as upgrades to a standard injection.
The same reasoning governs when we use bone marrow aspirate concentrate, Lipogems, or intradiscal orthobiologics instead. These are different biologic strategies with different intended targets, and the question “was this delivered to the target that matches the hypothesis?” belongs alongside the dose question.
What to ask before you agree to an injection
- What is the target platelet dose, and how is it defined? Per injection, per microliter, or cumulative across the course.
- Is the dose measured or assumed? Ask whether the final concentrate is quantified rather than estimated from the device specification.
- Leukocyte-rich or leukocyte-poor, and why? The answer should reference your target tissue.
- How is red cell contamination and pre-activation controlled? These are preparation-handling questions with published relevance.
- Where exactly is it being delivered, and on what hypothesis? Intra-articular, intraosseous, subchondral, or intradiscal placement should follow a stated clinical reason.
- How will response be judged, and when would the plan change? Agree the checkpoints before the first injection, not after the third.
Regen.MD is at 4477 Woodson Rd, Suite 103, St. Louis, MO 63134, next to St. Louis Lambert International Airport; details are on our St. Louis clinic page. Entry is a paid, physician-led Clinical Evaluation.
Find out what is actually driving your pain
Regen.MD begins with a physician-led Clinical Evaluation — a review of your history, imaging, and metabolic data, and a written terrain roadmap. Evaluation is contingent upon review of your data.
Questions? Call (314) 295-3000 or text (314) 886-5902.
What this practice actually uses
The formulation questions above are not left open here. Regen.MD prepares platelet-rich plasma leukocyte-poor — no white blood cells and no red blood cells — activated with calcium chloride, at a platelet concentration of two to three times baseline, with higher dosing in the six to twelve times range.
The target is a measured dose of more than ten billion platelets delivered per joint. Measured rather than assumed: platelet yield varies between patients and between draws, which is why a protocol expressed only as a multiple of baseline can deliver very different absolute doses to two people on the same day. That is the practice’s specification, not a finding from any single trial.
Frequently Asked Questions
Is there a platelet dose that matters most?
In sports medicine indications including osteoarthritis, tendinopathy, and muscle injury, a 2025 narrative review reports that optimal outcomes are achieved above 3.5 billion platelets per injection, with cumulative doses of 10 to 12 billion across a course. That is a review-level target rather than a rule for every patient, so the useful step is asking how your own protocol defines and verifies dose — the delivery options are described on our orthobiologics services page.
Which preparation factors have the biggest effect?
The published ones are leukocyte profile, red blood cell contamination, and pre-activation during processing, all of which change what is actually injected rather than merely how it is labelled. How we work those variables into a plan is set out in our approach to clinical evaluation.
Why did my first injection help more than my second?
There is no established explanation for that pattern, and anyone who offers you a confident one is going beyond the evidence; differences in preparation, delivery target, and what else changed in your rehabilitation are all plausible contributors. The honest answer is that it needs re-examination rather than a repeat, which is where the conditions we evaluate and the original diagnosis get revisited.
Does intraosseous or subchondral delivery work better than a standard injection?
They are not upgrades — they are different targets, chosen when the clinical hypothesis points at bone-adjacent structures rather than the joint space, and dose and preparation still govern what arrives there. Where PRP sits relative to bone marrow aspirate concentrate and Lipogems is covered on our orthobiologics services page.
Can peptide medicine be part of the same plan as PRP?
It can be part of the same conversation, but it is assessed separately and it is a clinical and educational subject here rather than a product for sale. The framing is on our peptide therapy page.
Sources
- Corsini A, Perticarini L, Palermi S, Bettinsoli P, Marchini A, “Re-Evaluating Platelet-Rich Plasma Dosing Strategies in Sports Medicine: The Role of the ’10 Billion Platelet Dose’ in Optimizing Therapeutic Outcomes — A Narrative Review,” Journal of Clinical Medicine, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC12027823/ — referenced for the platelet dose thresholds (above 3.5 billion per injection, 10 to 12 billion cumulative) in musculoskeletal sports medicine indications; for leukocyte-poor PRP demonstrating superior efficacy to leukocyte-rich PRP in intra-articular use while remaining debated in tendon and muscle; for red blood cell contamination and pre-activation being detrimental to effectiveness; for the low rate of comprehensive protocol description and quantitative composition reporting in published PRP trials; and for the methodological error and reliability findings in the PRP literature.
- “Platelet-rich plasma (PRP) in osteoarthritis (OA) knee: Correct dose critical for long term clinical efficacy,” Scientific Reports, volume 11, article 3971, 2021, https://www.nature.com/articles/s41598-021-83025-2 — randomized study of 150 patients with knee osteoarthritis. Referenced for the finding that adding a 1 micron filtration step to manual PRP processing improved platelet recovery to as much as 90%. Note: this paper has a published Author Correction (https://www.nature.com/articles/s41598-021-98365-2) relating to incorrect MRI images in Figure 3; the correction does not affect the preparation finding cited here.